IL-2 Variant H9T enhanced T Cell Engineering Service
Creative Biolabs provides researchers with functionally superior T cell products. We offer customized ex vivo expansion and modification protocols utilizing the H9T mutein to guarantee high T cell stemness and enhanced metabolic fitness. Clients receive advanced analytical data, including a full certificate of analysis and persistence & exhaustion risk profiles. By partnering with us, you can expect to accelerate your pre-clinical development timeline and transition into advanced translational studies with a highly potent and selectively engineered cellular product.
Introduction What We Can Offer Workflow Why Creative Biolabs Customer Reviews FAQs Related Services Contact Us
Advancing Cell Therapy with IL-2 Variant H9T
The use of wt-IL-2 in cell therapy is severely limited by its broad pleiotropy, which leads to Treg expansion and systemic side effects like VLS. The IL-2 variant H9T enhanced T cell engineering service leverages the power of locus mutation to create a selective IL-2 mutein, H9T. This variant preferentially signals through the intermediate-affinity CD122/CD132 receptor on effector T and NK cells. This strategy actively maintains the master transcription factor TCF-1, ensuring the manufactured cells possess the stemness and metabolic fitness required to become highly persistent, anti-tumor memory cells in vivo, representing a critical advancement in orthogonal cytokine engineering.
Discover how we can help - request a consultation.
Fig.1 The cytokine engineering increases the availability and specificity of cytokines for CD8+ T cells. 1
What We Can Offer
Phenotypic Customization
Tailored expansion protocols that fine-tune TCF-1 expression and metabolic fitness according to the client's specific research target (e.g., solid tumor vs. liquid malignancy).
Proprietary H9T Technology
Exclusive access to the H9T mutein, which selectively drives proliferation via the CD122/CD132 receptor, preventing off-target Treg expansion - a key competitive advantage for Creative Biolabs.
Comprehensive Quality Control (QC)
Integration of Quality-by-Design (QbD) principles, including advanced in-process controls to guarantee the final product's potency and longevity.
Toxicity Risk Mitigation
The manufacturing process is designed to eliminate the need for systemic wt-IL-2 post-infusion, drastically lowering the risk of severe in vivo side effects and simplifying project management.
IL-2 Variant H9T enhanced T Cell Engineering Service at Creative Biolabs
Why Choose Us?
|
Core Features
|
Key Advantages
|
|
Unparalleled Selectivity
|
H9T exclusively targets the CD122/CD132 dimer, preventing the off-target proliferation of inhibitory Treg cells, a severe limitation of all wt-IL-2 protocols.
|
|
Guaranteed Stemness and Persistence
|
We guarantee that our protocols yield a high percentage of TCF-1+ CD8+ T cells, which are required for long-term tumor eradication. This is the biological foundation of durable functional responses.
|
|
Risk Mitigation
|
The H9T approach mitigates the risk of severe VLS and other in vivo side effects associated with high-dose wt-IL-2, leading to potentially safer and more manageable in vivo study protocols.
|
To experience the Creative Biolabs advantage, get a quote today.
Customer Reviews
-
Superior TCF-1 Retention
Using Creative Biolabs' service in our research improved the TCF-1 retention rate in our engineered TCR-T cells, confirming the phenotype required for long-term T cell memory. This feature is a game-changer when comparing the product to wt-IL-2 expanded cells, which rapidly convert to the exhausted phenotype. – J**f W.
-
Effective Metabolic Reprogramming
Creative Biolabs' service in our research has significantly facilitated the metabolic reprogramming of our CAR-T products. The enhanced mitochondrial function provides a critical advantage for cell survival in the hypoxic TME. We are now using this platform as our gold standard for all solid tumor applications. – M**k L.
FAQs
Q: How does the H9T variant specifically address the safety concerns associated with high-dose wt-IL-2?
A: Wt-IL-2 side effects, notably vascular leak syndrome (VLS), are driven by its non-selective activation of all IL-2 receptor-expressing cells, including endothelial cells. H9T is engineered with minimized CD25 affinity, preventing the non-specific, systemic activation that causes severe adverse events.
Q: Is the H9T method compatible with my existing CAR-T or TCR-T vector system?
A: Yes. The H9T variant is incorporated as a soluble factor in the cell culture media during the expansion phase. It is entirely compatible with standard lentiviral, retroviral, and non-viral genetic modification methods. Our process is designed to seamlessly integrate into your current manufacturing flow, providing an immediate upgrade in cell quality without altering your existing gene delivery strategy.
Related Services
Immuno-oncology Immunophenotyping Service
Comprehensive analysis packages, including proprietary metabolic assays and TCF-1 expression profiling, to provide deep insights into the quality and function of T cell products.
Learn More →
Function Assays for Immune Checkpoint
Specialized functional assays focused on assessing the susceptibility of H9T-enhanced T cells to exhaustion in chronic antigen stimulation models and evaluating their response to co-administered checkpoint inhibitors.
Learn More →
How to Contact Us
Creative Biolabs' IL-2 variant H9T enhanced T cell engineering service is positioned as a pivotal innovation in durable cell therapy research. Collaboration with Creative Biolabs is designed to facilitate the attainment of robust, sustained functional success. Please contact us.
Reference
-
Yao, Zhouchi et al. "Focusing on CD8+ T-cell phenotypes: improving solid tumor therapy." Journal of experimental & clinical cancer research : CR vol. 43,1 266. 28 Sep. 2024. Distributed under an Open Access license CC BY 4.0, without modification. https://doi.org/10.1186/s13046-024-03195-5
For Research Use Only | Not For Clinical Use
